Tilfrinib是一种选择性的Brk/PTK6抑制剂，对Brk的IC50值为3.15nM。
Cas No.:1600515-49-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Tilfrinib is a selective Brk/PTK6 inhibitor with an IC₅₀ value of 3.15nM for Brk[1-2]. Tilfrinib is primarily used in cancer-related research[3-4].
In vitro, Tilfrinib (0-20μM) was administered to human lung adenocarcinoma cell lines PC9 and H1975 for 24-48 hours. Tilfrinib significantly inhibited PTK6 protein expression and reduced cell viability in a dose-dependent manner. Tilfrinib also suppressed colony formation, migration, and invasion capabilities in PC9 and H1975 cells, and induced apoptosis. Tilfrinib upregulated PD-L1 expression in the treated cells[4]. ETV4 WT-induced UM-UC-3 cells were treated with Tilfrinib (20μM) for 36 hours. Tilfrinib inhibited PTK6 and reduced the expression of CXCL1 or CXCL8 in cells[5].
References:
[1] Mahmoud KA, Krug M, Wersig T, et al. Discovery of 4-anilino α-carbolines as novel Brk inhibitors. Bioorg Med Chem Lett. 2014 Apr 15;24(8):1948-51.
[2] Chen B, Liu B, Chen J, et al. PTK6 drives HNRNPH1 phase separation to activate autophagy and suppress apoptosis in colorectal cancer. Autophagy. 2025 Aug;21(8):1680-1699.
[3] Jerin S, Harvey AJ, Lewis A. Therapeutic Potential of Protein Tyrosine Kinase 6 in Colorectal Cancer. Cancers (Basel). 2023 Jul 21;15(14):3703.
[4] Xiong RH, Yang SQ, Li JW, et al. Identification of immune-associated biomarker for predicting lung adenocarcinoma: bioinformatics analysis and experiment verification of PTK6. Discov Oncol. 2024 Apr 4;15(1):102.
[5] Zhang Q, Liu S, Wang H, et al. ETV4 Mediated Tumor-Associated Neutrophil Infiltration Facilitates Lymphangiogenesis and Lymphatic Metastasis of Bladder Cancer. Adv Sci (Weinh). 2023 Apr;10(11):e2205613.
Tilfrinib是一种选择性的Brk/PTK6抑制剂，对Brk的IC50值为3.15nM[1]。Tilfrinib主要用于癌症相关的研究[2-3]。
在体外，Tilfrinib（0-20μM）处理人肺腺癌细胞PC9和H1975细胞24-48小时，Tilfrinib显著抑制PTK6蛋白表达，并以剂量依赖的方式降低细胞活力。Tilfrinib抑制了PC9和H1975细胞的克隆形成、迁移和侵袭能力，诱导细胞凋亡。Tilfrinib还上调了细胞PD-L1的表达[4]。Tilfrinib（20μM）处理ETV4 WT诱导的UM-UC-3细胞和TAN细胞36小时，Tilfrinib可抑制PTK6，并降低细胞中CXCL1或CXCL8表达[5]。
| Cell experiment [1]: | |
Cell lines | PC9 and H1975 cells (human lung adenocarcinoma cell lines) |
Preparation Method | PC9 and H1975 cells were maintained in DMEM or RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were treated with Tilfrinib at concentrations of 0–20μM for 24–48 hours. |
Reaction Conditions | 0–20μM; 24–48h. |
Applications | Tilfrinib significantly inhibited PTK6 protein expression and reduced cell viability in a dose-dependent manner. Tilfrinib suppressed colony formation, migration, and invasion capabilities of lung adenocarcinoma cells, while inducing apoptosis. Additionally, Tilfrinib treatment upregulated PD-L1 expression, suggesting a potential immunomodulatory role. |
References: | |
| Cas No. | 1600515-49-8 | SDF | |
| Canonical SMILES | OC1=CC=CC(NC2=CC=NC3=C2C4=C(C=CC=C4)N3)=C1 | ||
| 分子式 | C17H13N3O | 分子量 | 275.3 |
| 溶解度 | DMSO: 23 mg/ml,Ethanol: 13 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6324 mL | 18.162 mL | 36.324 mL |
| 5 mM | 726.5 μL | 3.6324 mL | 7.2648 mL |
| 10 mM | 363.2 μL | 1.8162 mL | 3.6324 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet